Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Sezary Syndrome 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Hodgkin Disease 1Hematologic Neoplasms 1Cytomegalovirus Infections 1

Interventions

fludarabine phosphate 5Whole-Body Irradiation 5Mycophenolic Acid 5Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4carmustine, poliferprosan 20 drug combination 2Sirolimus 2Melphalan 2Etoposide 2Cytarabine 2Cyclophosphamide 2Carmustine 2venetoclax 1letermovir 1ibrutinib 1Tacrolimus 1Stem Cell Transplantation 1Interleukin-15 1Hematopoietic Stem Cell Transplantation 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Prolymphocytic, T-Cell × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡